OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II studyECCO '18 Vienna
2018
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
2018
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
2018
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targetsECCO '18 Vienna
2018
OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory moleculesECCO '18 Vienna
2018
OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS studyECCO '18 Vienna
2018
OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programmeECCO '18 Vienna
2018
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populationsECCO '18 Vienna
2018
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort studyECCO '18 Vienna
2018
OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammationECCO '18 Vienna
2018
P001: Establishment of in vitro human model for ulcerative colitis by using human colon organoid cultureECCO '18 Vienna
2018
P002: Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 familyECCO '18 Vienna
2018
P003: Identification of a novel therapeutic agent for treating Crohn’s disease guided by systems medicineECCO '18 Vienna
2018